Intercepting Cancer Communiques: Exosomes as Heralds of Malignancy  by Hingorani, Sunil R.
Cancer Cell
PreviewsIntercepting Cancer Communiques: Exosomes
as Heralds of MalignancySunil R. Hingorani1,2,3,*
1Clinical Research Division
2Public Health Sciences Division
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
3Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA 98195, USA
*Correspondence: srh@fhcrc.org
http://dx.doi.org/10.1016/j.ccell.2015.07.015
In clinical oncology, detecting and treating disease as early as possible is the brass ring to be grasped. Does a
new test based on circulating exosomes bring it closer for patients with pancreas cancer?Most solid tumors are incurable once they
metastasize, making prevention and early
detection primary goals. For pancreatic
ductal adenocarcinoma (PDA), which is
highly lethal even when resectable, the
stakes and standards for early detection
are even higher. This challenge was taken
up recently using a novel approach based
on circulating exosomes (crExos) (Melo
et al., 2015).
A subtype of extracellular membrane
vesicles (EV), exosomes are formed in
the endolysosomal pathway by intralumi-
nal budding into intracellular structures
known as multivesicular bodies (MVBs)
(Colombo et al., 2014). Fusion of MVBs
with the plasma membrane releases
their enclosed vesicles extracellularly
(Figure 1). Described over 30 years ago
as a means of receptor shedding, exo-
somes were not recognized as more
than carriers of cellular detritus until their
ability to modulate immunity was revealed
over a decade later (Raposo et al., 1996).
Packed with proteins and nucleic acids,
exosomes can influence the biology of
recipient cells with which they fuse. They
can also be exploited to promote the
pathophysiology of various diseases and
pre-metastatic niche conditioning in
malignancy.
Melo et al. (2015) identified a subset of
crExosmarked by a specific proteoglycan
(PG) as being almost uniquely present
in patients with preinvasive and invasive
PDA and absent from healthy controls
and those with benign pancreatic dis-
eases (BPDs). The authors first performed
proteomic analyses on exosomes from
cancer and non-cancer cell lines and
identified 48 cancer-specific proteins.
Among these was glypican-1 (GPC1), amembrane associated, glycophospha-
tidyl-anchored heparan sulfate PG
(HSPG), which is overexpressed in human
PDA and confers responsiveness to hep-
arin-binding growth factors (Kleeff et al.,
1998). Experiments on transplantable tu-
mor models confirmed that GPC1 was
found exclusively on exosomes from im-
planted cancer cell lines.
Melo et al. (2015) then characterized
crExos from patients. They found that
exosomes enriched from the sera of
PDA patients were more numerous and
smaller than their normal sera counter-
parts. In an initial (‘‘discovery’’) cohort,
very few crExos from normal sera were
GPC1+ (mean 2.3%, range 0.3%–4.7%)
compared with crExos from PDA patient
sera (mean 45%, range 10%–100%).
Thus, by setting a threshold of 8%
GPC1+ crExos, PDA patients (n = 190)
and healthy controls (n = 100) could be
distinguished with 100% sensitivity and
specificity. GPC1+ crExos were also rare
in samples from patients with BPD
(n = 26; mean 2.1%). A small sample
set (n = 5) of symptomatic patients
with confirmed intraductal pancreatic
mucinous neoplasms (IPMNs)—one of
whom also had invasive disease—could
also be distinguished from healthy con-
trols, though not as clearly from BPD or
PDA. These general relationships held up
in a separate smaller set of ‘‘validation’’
samples. However, the ‘‘validation’’ sam-
pleswerecollectedat the same twohospi-
tals as the ‘‘discovery’’ set, and a different
cut-off point of 12% GPC1+ crExos was
applied. These factors, together with the
relatively small numbers ofBPDandprein-
vasive disease samples, make the claims
for validation and perfect sensitivity andCancer Cell 28specificity less certain. Freely circulating
GPC1 measured by ELISA performed
no better than carbohydrate antigen 19-9
(CA19-9), the only currently available
marker for PDA. Thus, both sensitivity
and specificity of GPC1 as a biomarker
for pancreas cancer depend critically
on its enrichment in crExos and, in this
instance, a flexible cut-point.
Only GPC1+ exosomes contained
mutant KRAS mRNA, and they also
appeared to correlate modestly with
overall metastatic burden, albeit with
widely overlapping ranges. GPC1+ crExos
decreased significantly in a subset of pa-
tients post-operatively, which correlated
with improved disease-free and overall
survival. Changes in serum CA19-9 levels
were less predictive, but the limited 7-day
post-operative window may have been
insufficient given the prolonged biphasic
serum decay properties of this antigen.
Finally, the authors complemented
these analyses with studies in a mouse
model of PDA based on targeted expres-
sion of oncogenic KrasG12D and condi-
tional biallelic deletion of Tgfbr2; these
mice develop rapidly progressive disease
and succumb by 8 weeks of age. The
ROC curve for experimental versus con-
trol mice once again had an AUC of 1.0;
however, GPC1+ crExos were also
increased in several mice despite the
absence of any histopathology, preinva-
sive or otherwise, suggesting the assay
had transcended merely detecting to
divining cancer: sentinels had become
seers.
If GPC1 is integral to, and not just
an indicator of, disease pathogenesis,
the possibilities for therapeutic targeting
broaden. Functioning as co-receptors,, August 10, 2015 ª2015 Elsevier Inc. 151
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Figure 1. GPC1 Marks Pancreas Cancer Exosomes
(A) Exosomes are formed by intraluminal budding as early endosomes (EE) mature into multivesicular
bodies (MVB). When MVB fuse with the plasma membrane (PM), exosomes are secreted into the micro-
environment and can enter the bloodstream. GPC1 is a heparan sulfate (hs) proteoglycan tethered to the
surface of cells and exosomes through a specific glycophosphatidyl linkage (yellow).
(B) Melo et al. (2015) report that GPC1+ circulating exosomes are frequent in the sera of patients with
preinvasive and invasive pancreas cancer but rare in healthy patients and those with benign pancreatic
disease (BPD).
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Previewscell surface glypicans shape the morpho-
genetic gradients of molecules such as
Hedgehog and Wingless during develop-
ment (Ha¨cker et al., 2005) and can guide
the internalization of exosomes and virus
particles (Christianson et al., 2013). It
may be possible to engineer and admin-
ister GPC1+ vesicles with specific pay-
loads to target the delivery of treatment.
Alternatively, perhaps metastasis can be
thwarted or at least diminished by disrupt-
ing GPC1. It will be important in this re-
gard to examine the overlap between the
GPC1+ exosomes described here and
those characterized in a contempora-
neous report on the induction of a pre-
metastatic niche through exosomal deliv-
ery of migration inhibitory factor (MIF) to
Kuppfer cells in the liver and the subse-
quent activation of pro-inflammatory
pathways (Costa-Silva et al., 2015). Not
explained in that study was how the exo-
somes were exclusively taken up by
Kuppfer cells. GPC1 was among the pro-152 Cancer Cell 28, August 10, 2015 ª2015 Eteins identified by Costa-Silva et al. (2015)
in their exosomal preparations, although
MIF was not described in Melo et al.’s
protein atlas of GPC1+ vesicles. The
specific subpopulations of recovered
EV, as well as their biological properties,
can change substantially depending on
methods of isolation and handling (Witwer
et al., 2013).
The performance reported here of the
GPC1 exosome assay in detecting PDA
dangles considerable translational prom-
ise, but envisioning the ideal clinical appli-
cation(s) is less straightforward. The per-
fect ROC curves distinguishing invasive
PDA from benign or no pancreatic dis-
ease, should they hold up in broader
testing—and economics permitting—
even suggest the potential for general
screening of the population, a rare feat
for any marker. The inability to distinguish
preinvasive from invasive disease gives
pause, however, because not all precur-
sors are destined to progress, and this de-lsevier Inc.fines a major clinical challenge. On the
other hand, identifying the biological sig-
nificance of persistent GPC1+ crExos in
some patients postoperatively could
inform subsequent management. For
example, if it reflects residual primary dis-
ease, then these patients might benefit
from a course of postoperative radio-
therapy, which is not otherwise routinely
used in all patients. If, instead, it repre-
sents a significant occult metastatic
disease burden, then these patients may
benefit from more intensive systemic
adjuvant therapy.
The work by Melo et al. (2015) has
advanced GPC1+ crExos through the first
and begun to address the second of five
phases for successful biomarker develop-
ment (Pepe et al., 2001), namely the ability
to detect clinically established disease.
Testing in cohorts collected at other insti-
tutions and establishing an immutable
threshold distinguishing positive and
negative disease will be required to fully
clear this hurdle. The next step would be
to scrutinize the assay’s ability to detect
occult disease, which would require
testing on pre-diagnostic samples. The
battlefield of biomarker discovery is lit-
tered with fallen candidates, and count-
less others have been relegated to a
forgotten purgatory of partial develop-
ment (Harsha et al., 2009). It also bears
remembering that the final phase
of biomarker development addresses
whether it matters to detect the cancer
earlier; in other words, whether a survival
benefit can be conferred with the knowl-
edge gained. Until we can change the nat-
ural history of this disease and not simply
assuage ourselves with the illusion of
progress from lead-time bias, the full po-
tential of an early-detection tool, no mat-
ter how robust, will not be realized.ACKNOWLEDGMENTS
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